Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation Clinical Trials

Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation

Explore clinical trials studying Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation. Study availability and eligibility vary by location and protocol.

1 public trial 1 recruiting study

Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation trial results

Recruiting

Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation

NCT06501625

Conditions: Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation
Locations: Cancer and Blood Speciality Clinic - Los Alamitos Los Alamitos, California, United States

Usc Norris Comprehensive Cancer Center Los Angeles, California, United States

Northwestern Medicine Chicago, Illinois, United States

Memorial Sloan Kettering Cancer Center New York, United States

View all 38 locations

View Trial Details